Brought to you by 
Agilent to pay $2.2bn for Dako AS
May 2012
Executive Summary
Expanding its presence in the diagnostics market, life sciences company Agilent Technologies Inc. will pay $2.2bn in cash to buy Dako AS (cancer testing) from private equity firm EQT Partners.
Deal Industry
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Cytology
- Molecular Diagnostics & Genetic Testing
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Payment Includes Cash
- Full Acquisition
- Intra-Biotech Deal
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Agilent to pay $2.2bn for Dako AS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice